High Paying US Jobs, Economic Empowerment


Revitalization of States through Federal Power

"Critical Field" Technology Innovation 


Maximized Profits on R&D and Investments

Prevention of Biochemical and Nuclear Proliferation


Homeland Security Technologies

National Council on Innovative Technology Commercialization

International Council on Innovative Technology Commercialization

Critical Field Innovations

Commercialization Programs

About Us


POP treatment for skin and autoimmune diseases: psoriasis, eczema, rheumatoid arthritis, T-cell lymphoma, among others


An inexpensive “at home treatment” of skin and autoimmune diseases without the side effects associated with comparable traditional therapy is protected by two Russian patents and is available for commercialization. A new patent on design of the photochemical reactor for POP-preparation and clinical methods for POP-treatment is being prepared.

Successful double blind clinical trial performed on numerous eczema patients. Successful preliminary clinical studies indicate that POP is efficient for treatment of psoriasis, cutaneous T-lymphoma, piodermia, rheumatoid arthritis and some other skin and autoimmune diseases. Relief was achieved after one week of POP-treatment with mean remission period of 8 months.

Traditionally the main and most effective treatment for skin and autoimmune diseases is PUVA therapy, that includes two stages: oral intake of drug- psoralen and the sequential whole body exposure to ultraviolet light. The necessary high doze UV-exposure causes skin and eye hypersensitivity to sunlight, sunburn, induction of cataract of eyes and increases the risk of skin cancer. It is also a very expensive procedure and is recommended to be performed in a hospital.

15 million Americans suffer from psoriases and eczema; The annual outpatient market for psoriases is $3 Billion; Large Market opportunities for all other diseases that can be treated; Treatment of African-Americans who have to be treated with a much higher UV-intensity with a dramatic increase in skin cancer risk creates an additional market opportunity

By irradiating the drug-psoralen solution itself (in vitro) before its oral intake a similar effect to PUVA treatment is achieved without the need for UV-irradiation. An amount of photo-treated psoralen can also be reduced 50 times to achieve comparable effect as can be achieved with a much larger dose of conventional psoralen in PUVA therapy. The elimination of the UV-exposure and considerable decrease in psoralen dose practically eliminates the side effects.